RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .
Decreased in vitro oxidizability of low‐density lipoprotein in hypercholesterolaemic patients treated with 3‐hydroxy‐3‐methyIgIutaryl‐CoA reductase inhibitors
Abstract . We studied the effects of the 3‐hydroxy‐3‐methylglutaryl‐CoA ( HMG‐CoA ) reductase inhibitors simvastatin and pravastatin on the in vitro susceptibility of low‐density lipoprotein ( LDL ) to oxidation . Twenty‐three hypercholesterolaemic patients ( mean serum cholesterol 9.7 mmol 1‐1 ) were treated with increasing doses of either simvastatin or pravastatin for 18 weeks . No significant differences in effect on lipid levels between the two drugs were found . Treatment result ed in lowering of total cholesterol and LDL‐cholesterol by maximally 30 % and 34 % , respectively . Chemical composition analysis showed that LDL particles contained relatively more protein and less free cholesterol and cholesteryl‐ester after treatment . The LDL cholesterol/protein ratio decreased from 1.24 ± 0.21 to 0.97 ± 0.23 ( n = 20 ) . By continuous monitoring of in vitro oxidation it appeared that LDL was less susceptible to oxidation after drug treatment . Maximal rate of diene production was significantly decreased from 19.7 ± 3.1 to 18.5 ± 3.3 nmol min‐1 mg‐1 LDL ; total diene production decreased significantly from 420.3 ± 67.6 to 380.5 ± 49.1 nmol mg‐1 LDL ; the lag time was unchanged throughout the study . These studies show that HMG‐CoA reductase inhibitors reduce the oxidizability of LDL by altering its composition
RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .